超重和肥胖成人患者利奈唑胺群体药代动力学及给药考量
该回顾性队列研究纳入112例超重或肥胖住院患者,构建利奈唑胺群体药代动力学模型并进行蒙特卡洛模拟。结果显示,估算肌酐清除率(CrCLCKD-EPI)是唯一改善模型拟合的协变量。剂量调整应基于CrCLCKD-EPI而非体型指标,部分患者需治疗药物监测。
要点
- 利奈唑胺剂量调整应基于CrCLCKD-EPI,而非体重或体型描述符。
- CrCLCKD-EPI < 130 mL/min/1.73 m²的凝固酶阴性葡萄球菌感染患者,450 mg q12h可能最优。
- CrCLCKD-EPI ≥ 60 mL/min/1.73 m²者,450 mg q8h可能最优;600 mg q8h因血小板减少风险不推荐。
核心结论
- 超重和肥胖成人患者的利奈唑胺剂量调整应基于CrCLCKD-EPI估算值,而非体型指标。
研究设计与样本
- 回顾性队列研究,纳入112例超重或肥胖住院患者,共352个谷浓度和293个峰浓度。
- 采用群体药代动力学建模和蒙特卡洛模拟评估PTA。
主要发现
- 最终混合饱和模型可解释88%的药物浓度随时间变异。
- CrCLCKD-EPI是唯一改善模型拟合的协变量。
关键数值与推荐
- 药效学靶值为AUC24/MIC > 100。
- 最大允许剂量定义为谷浓度 > 8.06 mg/L(与血小板减少相关)概率 ≤ 25%的剂量。
- CrCLCKD-EPI < 130 mL/min/1.73 m²且为凝固酶阴性葡萄球菌感染时,450 mg q12h可能最优。
- CrCLCKD-EPI ≥ 60 mL/min/1.73 m²时,450 mg q8h可能最优。
- 600 mg q8h因血小板减少风险不可接受,不推荐。
临床怎么用
- 根据CrCLCKD-EPI估算值调整利奈唑胺剂量,无需依据体重。
- CrCLCKD-EPI ≥ 130 mL/min/1.73 m²和/或合并使用P-糖蛋白调节剂者需进行治疗药物监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Linezolid is an anti-Gram-positive antimicrobial agent used at a fixed dose of 600 mg every 12 h. OBJECTIVES: The objective of this study was to assess the population pharmacokinetics and pharmacodynamics of linezolid in a retrospective cohort of overweight and obese hospitalized patients. PATIENTS AND METHODS: Population pharmacokinetic and Monte Carlo simulations were conducted to assess the probability of target attainment (PTA) of an area under the concentration-time curve from time zero to 24 h (AUC24)/minimum inhibitory concentration (MIC) ratio > 100, defined as the pharmacodynamic target of efficacy, with incremental candidate dosages. Maximum permissible doses were defined as those causing a ≤ 25% of probability of a linezolid trough of > 8.06 mg/L, associated with thrombocytopenia. The cumulative fraction of response was calculated for the permissible linezolid doses by testing the PTA against the MIC distributions of a large collection of Staphylococci and Enterococci. RESULTS: A total of 352 trough (minimum) and 293 peak (maximum) linezolid concentrations from 112 patients were included. The final mixed-saturative model accounted for 88% of drug concentrations variability over time, and estimated creatinine clearance [by means of the Chronic Kidney Diseases Epidemiology formula (CrCLCKD-EPI)] was the only covariate that improved the model fit. Dose reduction to 450 mg every 12 h may be optimal for patients with coagulase-negative staphylococcal infections and a CrCLCKD-EPI < 130 mL/min/1.73 m2. Dose escalation to 450 mg every 8 h may be optimal for patients with a CrCLCKD-EPI ≥ 60 mL/min/1.73 m2. Escalation to 600 mg every 8 h should not be recommended due to an unacceptable high risk of thrombocytopenia. Patients with CrCLCKD-EPI ≥ 130 mL/min/1.73 m2 and/or co-medication with P-glycoprotein modulators require therapeutic drug monitoring to optimize linezolid doses. CONCLUSIONS: Dosage adjustments of linezolid in this population should be based on CrCLCKD-EPI estimates, rather than on body size descriptors.
引用
- Cojutti P, Pai MP, Pea F, et al. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. Clin Pharmacokinet. 2018. PMID: 29080937. doi:10.1007/s40262-017-0606-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。